Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPI-1002 for MAKE prevention in cardiac surgery
NCT03510897Phase 3Terminated
- Sponsor
- Quark Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 11
01
Overview
A Phase 3 trial of teprasiran in acute kidney injury (AKI), sponsored by Quark Pharmaceuticals. Started Jun 2018; status: terminated.
02
Drugs
teprasiran
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03510897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510897.